These pwCF, and individuals with CFTR variants that are ineligible for or intolerant to CFTR modulator therapy (an estimated 10% of the global CF population), may therefore benefit from treatments that reduce neutrophilic inflammation, such as inhibition of NSP activity, as an approach distinct from the restoration of airway ion transport. The gene discussed is CFTR; the disease is cystic fibrosis.